REG - Genedrive PLC - Result of RetailBook Offer

GenedriveAnnouncement

01/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250401:nRSA0175Da&default-theme=true

RNS Number : 0175D  Genedrive PLC  01 April 2025

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW
PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON
LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE,
PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO
THE UNITED STATES, CANADA OR JAPAN.

genedrive plc

 

("genedrive" or the "Company")

 

Result of RetailBook Offer

 

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company
announced on 27 March 2025 the launch of a fundraising comprising a
Subscription in conjunction with a retail offer via RetailBook (the
"RetailBook Offer", together with the Subscription, the "Fundraising").

 

The Company is pleased to announce that the RetailBook Offer successfully
completed and closed at 5.00 p.m. on 31 March 2025 and that it has
conditionally raised approximately £226,308.92 in the RetailBook Offer
through the issue of 15,087,261 new Ordinary Shares at the Issue Price of 1.5
pence per share.

 

Accordingly, following the close of the RetailBook Offer, the Company has
conditionally raised gross proceeds of approximately £1.23 million at the
Issue Price via the Fundraising requiring the issue and allotment of
81,753,927 new Ordinary Shares (the "Fundraising Shares").

 

Capitalised terms used in this announcement shall, unless defined in this
announcement or unless the context provides otherwise, bear the same meaning
ascribed to such terms in the Equity fundraise announcement.

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for the Fundraising
Shares to be admitted to trading on trading on AIM. Admission is expected to
take place and dealings in the Fundraising Shares are expected to commence at
8.00 a.m. on 3 April 2025, at which time it is also expected that the
Fundraising Shares will be enabled for settlement in CREST.

 

Immediately following Admission, the issued share capital of the Company is
expected to comprise 624,895,408 Ordinary Shares. Each Ordinary Share has one
voting right and no Ordinary Shares are held in treasury. From Admission, this
figure may be used by Shareholders as the denominator for the calculation by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

Enquiries:

 

 genedrive plc                                     +44 (0) 161 989 0245

 Gino Miele: CEO / Russ Shaw: CFO
 RetailBook Limited                                capitalmarkets@retailbook.com

 Nick Smith / Michael Ward

 Peel Hunt LLP, Nominated Adviser and Broker       +44 (0) 20 7418 8900

 James Steel
 Walbrook PR Ltd (Media & Investor Relations)      +44 (0) 20 7933 8780 or genedrive@walbrookpr.com

 Anna Dunphy                                       +44 (0) 7876 741 001

 

Notes:

References to times in this Announcement are to London time unless otherwise
stated. The times and dates mentioned throughout this Announcement may be
adjusted by the Company in which event the Company will make an appropriate
announcement to a Regulatory Information Service giving details of any revised
dates and the details of the new times and dates will be notified to London
Stock Exchange plc (the "London Stock Exchange") and, where appropriate,
Shareholders. Shareholders may not receive any further written communication.

 

IMPORTANT INFORMATION

This Announcement is not for publication or distribution, directly or
indirectly, in or into the United States of America. This Announcement is not
an offer of securities for sale into the United States. The securities
referred to herein have not been and will not be registered under the U.S.
Securities Act of 1933, as amended, and may not be offered or sold in the
United States, except pursuant to an applicable exemption from registration.
No public offering of securities is being made in the United States.

 

This Announcement and the information contained herein, is restricted and is
not for publication, release or distribution, directly or indirectly, in whole
or in part, in or into Australia, Canada, the Republic of South Africa, Japan
or any other jurisdiction in which such publication, release or distribution
would be unlawful.  Further, this Announcement is for information purposes
only and is not an offer of securities in any jurisdiction.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIEAXDFDAFSEFA